Share on StockTwits
 

Natus Medical (NASDAQ:BABY) CEO James B. Hawkins sold 75,000 shares of the company’s stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $25.88, for a total transaction of $1,941,000.00. Following the completion of the transaction, the chief executive officer now directly owns 468,844 shares in the company, valued at approximately $12,133,683. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Natus Medical (NASDAQ:BABY) traded up 3.67% during mid-day trading on Monday, hitting $26.24. 640,368 shares of the company’s stock traded hands. Natus Medical has a 1-year low of $11.40 and a 1-year high of $26.98. The stock has a 50-day moving average of $24.87 and a 200-day moving average of $19.24. The company has a market cap of $800.2 million and a price-to-earnings ratio of 34.20.

Natus Medical (NASDAQ:BABY) last posted its quarterly earnings results on Wednesday, January 29th. The company reported $0.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.32 by $0.05. The company had revenue of $90.60 million for the quarter, compared to the consensus estimate of $89.12 million. During the same quarter in the previous year, the company posted $0.29 earnings per share. The company’s revenue for the quarter was down .2% on a year-over-year basis. Analysts expect that Natus Medical will post $1.19 EPS for the current fiscal year.

Separately, analysts at Raymond James raised their price target on shares of Natus Medical from $21.00 to $25.00 in a research note on Tuesday, November 26th.

Natus Medical Incorporated (NASDAQ:BABY) is a provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.